Chester County News and Community Website
Every September — World Alzheimer’s Month — the public is reminded of startling statistics about this devastating form of dementia that affects memory, thinking, and behavior. The lifetime risk for …
Understanding Alzheimer’s: Key Signs and Proactive Steps for Caregivers Read More
MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) announced new preclinical data showing the positive combined effects of its lead compound, buntanetap, with the GLP-1 agonist dulaglutide (Trulicity®) in an …
Annovis Bio Shows Synergistic Effect of Buntanetap and Dulaglutide in Alzheimer’s Treatment Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has received approval from the U.S. Food and Drug Administration (FDA) to transition to a new solid form of buntanetap in future …
Annovis Bio Gains FDA Approval for New Form of Neurodegenerative Drug Read More
WASHINGTON, D.C. — On Tuesday, the Food and Drug Administration (FDA) approved Kisunla (donanemab-azbt) injection for the treatment of Alzheimer’s disease. This approval marks a major milestone in the fight …
FDA Approves Kisunla for Alzheimer’s Treatment, Marking Significant Progress Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) will host an investor webcast on July 2, 2024, at 4:30 PM ET to discuss recent progress and future plans for its …
Annovis Bio to Host Investor Webcast on Buntanetap Developments Read More
PHILADELPHIA, PA — The Global CEO Initiative on Alzheimer’s Disease (CEOi), led by UsAgainstAlzheimer’s, has announced the publication of its latest recommendations on blood-based biomarker (BBM) tests in the journal …
New Standards Aim to Improve Early Alzheimer’s Diagnosis Through Blood Tests Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has announced promising results from its recent Phase II/III clinical trial for its lead drug candidate, Buntanetap, targeting Alzheimer’s disease (AD). The …
Annovis Bio’s Alzheimer’s Drug Shows Promise in Phase II/III Trial Read More